Atea Pharmaceuticals Inc
NASDAQ:AVIR
Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The firm is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The firm is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. The company is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The firm is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The firm is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The firm is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. The company is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The firm is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
Phase III HCV Program: Atea is on track to complete enrollment for its North American Phase III HCV trial next month, with top-line results expected mid-2026.
Pipeline Expansion: The company announced two new candidates for hepatitis E, targeting a large unmet need in immunocompromised patients; Phase I is anticipated to start mid-2026.
Financial Position: Atea ended Q3 2025 with $329.3 million in cash, cash equivalents, and marketable securities, projecting a cash runway through 2027.
Differentiation: New data highlight a unique dual mechanism of action for bemnifosbuvir, strengthening its potential as a best-in-class HCV therapy.
Share Repurchase: Atea completed its $25 million share buyback program, retiring 7.6 million shares.
No Drug-Drug Interactions: Recent data show no significant interactions with common acid-reducing therapies, a key differentiator from competitors like Epclusa.
